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Background: Venous thromboembolism (VTE) preventive strategies are frequently underutilized and often inadequately administered.
Methods: We queried our hospital’s medication administration record with the goal of identifying barriers to pharmacological prophylaxis. We 
evaluated nurses’ reasons for delayed or omitted prophylaxis doses, comparing unfractionated heparin (UFH) 5,000 units twice daily (BID) or three 
times daily (TID) to low molecular weight heparin (LMWH). We determined which strategy had the best adherence for correct timing and dose 
administration.
Results: We identified 250 consecutive patients, hospitalized for at least four days, and receiving pharmacological prophylaxis for VTE. Of LMWH 
patients, 78% received all ordered doses compared with 54% of BID UFH and 45% of TID UFH (p < 0.001). Adherence, defined as the ratio of doses 
administered to those ordered, to physicians’ medication orders was greatest with LMWH (94.9%) when compared with UFH TID (87.8%), and UFH 
BID (86.8%) regimens (p < 0.001). Patient refusal was the most frequently documented reason for dose omission, representing nearly 60% of 
patients receiving UFH and 40% of patients receiving LMWH.
Conclusions: We conclude that patients often refuse medications for VTE prevention because they dislike injections or do not understand the 
rationale. Efforts should focus on improving the consistency of anticoagulant dose administration by fostering patient education regarding VTE and 
its prevention.
Pharmacologic VTE Prophylaxis Administration
Outcomes and Adherence
LMWH
N=125 Patients
UFH Twice Daily
N=28 Patients
UFH Three Times Daily
N=97 Patients
P-Value
Number of scheduled doses (%) 648 (100) 204 (100) 1195 (100) 1.0
Doses administered (%) 615 (94.9) 177 (86.8) 1049 (87.8) <0.001
Doses omitted (%) 33 (5.1) 27 (13.2) 146 (12.2) <0.001
Patients that received 100% of doses (%) 97 (77.6) 15 (53.6) 44 (45.4) <0.001 
Interval in hours between administered doses 24.42±5.09 12.74±2.13 8.70±1.02 <0.001 
Reasons for Omission Dose Refused by Patient 13 (39.4) 16 (59.3) 61 (41.8) 0.21
Held Per Physician 9 (27.3) 2 (7.4) 24 (16.4) 0.12
Patient Off Floor 5 (15.2) 3 (11.1) 17 (11.6) 0.84
Patient Unable 0 (0.0) 0 (0.0) 2 (1.4) 0.66
